Host: The 94th Annual Meeting of the Japanese Pharmacological Society
Name : The 94th Annual Meeting of the Japanese Pharmacological Society
Number : 94
Location : Sapporo
Date : March 08, 2021 - March 10, 2021
The environment surrounding the pharmaceutical industry is changing drastically. For example, the progress of aging in developed countries, the worsening of medical finance, the rise of new technologies such as genomic medicine and AI, and the diversification of health and medical needs of patients and people.Under these changes, what should we do to contribute to the extension of healthy life expectancy? JPMA issued "Policy recommendations 2019" in 2019. We should not only create drugs for the treatment of diseases but also engage in R & D for prevention and preemptive medicine. To this end, it is essential to create innovation that incorporates innovative technologies such as health care big data, AI, and genomic medicine.With these changes, the form of open innovation has been expanding from one-one-one collaborative research to many-to-many collaborative research. In order to create innovation in the future, we need an ecosystem constructed by a wide range of stakeholders from industry, academia, and government.In this lecture, I would like to introduce examples of open innovation that has been conducted in the pharmaceutical industry and discuss the direction of future open innovation.
